This site uses cookies, including third-party cookies, that help us to provide and improve our services. Read More

Plasma Fractionation Market

Plasma Fractionation Market

Rising Prevalence of Infectious and Chronic Diseases to Stimulate the Plasma Fractionation Market Growth during 2021-2031

Plasma Fractionation Market
  • Mar-2022
  • List of Tables : 37
  • List of Figures : 77
  • 170 Pages
  • Healthcare

Market Snapshot

According to Fact.MR, the market for plasma fractionation is anticipated to surpass a CAGR of 7% through 2031, expected to surpass a value of US$ 38 Bn by the end of the forecast period.

The growing demand is due to the increase in respiratory problems faced by various age group of people especially the geriatric population. This, in turn, has increased the need for plasma collection centres. In addition, use of plasma derived immunoglobulins to treat inflammatory diseases has affected the market positively. 

Key Points Covered in Plasma Fractionation Industry Survey

  • Market estimates and forecast 2016-2031
  • Key drivers and restraints impacting market growth
  • Segment-wise, Country-wise, and Region-wise Analysis
  • Competition Mapping and Benchmarking
  • Market Share Analysis
  • Key Product Innovations and Regulatory Climate
  • COVID-19 Impact on Plasma Fractionation Market and How to Navigate
  • Recommendation on Key Winning Strategies

Plasma Fractionation Revenue Analysis 2016-2020 Vs Future Forecast 2021-2031

As per Fact.MR - a market research and intelligence provider, the plasma fractionation market was valued at US$ 19 Bn in 2020, experiencing a historical CAGR worth 5% from 2016-2020.

Plasma derived immunoglobulins are being increasingly used in multiple clinical indications such as autoimmune and inflammatory diseases. The plasma fractionation market has heavily invested in therapies such as Ceruloplasmin, IgA and Plasmin.

In addition, burgeoning investments in innovation and technological advancements in efficient and cost-effective procedures for fractioning proteins shall provide impetus to the market.

On the back of the aforementioned trends, the global plasma fractionation market is poised to experience an uptick in the forecast period (2021-2031). Anticipated CAGR for the market is pegged at a staggering 7%.

How are Increasing Incidences of Infectious Diseases Spurring Adoption?

Life threatening ailments that are a result of stress, infections, congenital deficiencies, trauma and immunological disorders have shown a massive upsurge.  This had led to plasma being majorly used in therapeutic areas in treating patients.

The birth of the novel coronavirus has increased respiratory diseases that directly infects the lungs. Certain patients face difficult due to high blood pressure and diabetes, along with this, family history plays a major role. Thus, to control the ailment, plasma fractionation is applied vastly.

Avail customized purchase options for your needs

How are Technological Advancements Anticipated to Fuel Expansion Prospects?

Advancement in technology has made detection of ailments easier. In addition, awareness of regular check-ups, follow up check-ups has pushed the growth of plasma fractionation.

Key players are investing in various therapies that will produce reliable results. Manufactures are focusing on therapies such as IgA, Plasmin and Ceruloplasmin. This, in turn, is has affected the market for plasma fractionation positively.

Country-wise Analysis

How is the Plasma Fractionation Industry Performing in the U.S?

The U.S market for plasma fractionation shall lay suzerainty during the forecast period, set to capture nearly 2/5th of the market revenue, expanding at a CAGR of 6.6%.

A robust healthcare sector along with continuous technological innovation shall accelerate demand for plasma fractionation in North America. Moreover, the prevalence of neurological and autoimmune diseases as well as haemophilia shall boost demand prospects for plasma fractionation.

What is Uplifting the growth of Plasma Fractionation in the Asian Market?

Asia shows a promising outlook for the growth of the plasma fractionation industry. Therapeutic applicability of plasma fractionation proteins is an important growth lever for the Asia-Pacific market.

Moreover, technological improvements in healthcare sectors of emerging economies are anticipated to pave way for exciting market prospects during the forecast period. Projected CAGR for the Asian market is pegged at a staggering 8%. Also, prevalence of immune and bleeding disorders have prompted investments in plasma fractionation techniques.

An Adaptive Approach to Modern-day Research Needs

Category-wise Insights

Why are Plasma Fractionation Therapies Increasing in the Neurological Domain?

The neurology segment is anticipated to enjoy the lion’s share of the plasma fractionation market. A spurt in neurological disorders is responsible for the growing scope of the neurology segment.

Fact.MR projects that neurological disorders plague more than 450 million people globally. The neurology segment shall account for more than 2/5th of the plasma fractionation market, growing at a CAGR of 7.2%.

What Expansion Prospects Lie Across the Immunology Segment?

Trailing behind is the immunology segment, expanding 1.5x during the forecast period. Rising popularity of immunoglobulins as an important treatment option for autoimmune and inflammatory diseases is anticipated to be a key growth driver.

The immunology segment is anticipated to capture almost one-third of the plasma fractionation market, surpassing a value of US$ 10 Bn by 2031.

Competitive Landscape

The plasma fractionation market consists of multiple players. Innovative product offerings and new product development are key growth strategies adopted by market players.

  • CSL Behring, for instance, markets the Privigen, Carimune, Snadoglobulin and Hizentra solutions. Sanquin produces four types of plasma products using various isolation techniques: coagulation factors, protease inhibitors, immunoglobulins and albumin. The company also offers contract fractionation services.
  • Biotest AG develops, manufactures and markets plasma proteins and biotherapeutic drugs. It leads in the field of plasma collection. Biotest AG presently develops plasma proteins for Primary Immune Deficiency (PID) and various hyperimmune products. Examples of the products offered are Varitect, Cytotect CP and Albiomin.

Interested to Procure The Data

Report Scope



Forecast Period


Historical Data Available for


Market Analysis

US$ Mn for Value & ‘000 Units for Volume

Key Regions Covered

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

Key Countries Covered

  • U.S
  • Canada
  • Brazil
  • Mexico
  • Germany
  • U.K
  • France
  • Spain
  • Italy
  • Russia
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • GCC
  • South Africa

Key Market Segments Covered

  • Product
  • Application
  • End User
  • Region

Key Companies Profiled

  • CSL Behring, Shire Plc.
  • Sanquin
  • Biotest AG
  • Baxter International Inc.
  • Kedrion
  • Octapharma USA Inc.


Available upon Request

Key Segments Covered

  • By Product :

    • Immunoglobulins for Plasma Fractionation
      • Intravenous Immunoglobulins
      • Subcutaneous Immunoglobulins
    • Coagulation Factor Concentrates for Plasma Fractionation
      • Factor VIII
      • Factor IXF
      • Factor XIII
      • Prothrombin Complex Concentrate
      • Von Willebrand Factor (VWF)
      • Fibrinogen Concentrates
    • Albumin for Plasma Fractionation
    • Protease Inhibitors for Plasma Fractionation
    • Other Plasma Products for Plasma Fractionation
  • By Application :

    • Plasma Fractionation for Neurology
    • Plasma Fractionation for Immunology
    • Plasma Fractionation for Haematology
    • Plasma Fractionation for Critical Care
    • Plasma Fractionation for Pulmonary Applications
    • Plasma Fractionation for Other Applications
  • By End User :

    • Plasma Fractionation for Hospitals & Clinics
    • Plasma Fractionation for Clinical Research Laboratories
    • Plasma Fractionation for Academic Institutions

- FAQs -

According to Fact.MR, sales of plasma fractionation therapeutic solutions are projected to surpass a CAGR of 7%

As of 2020, the plasma fractionation industry was valued at US$ 19 Bn

From 2016 to 2020, plasma fractionation demand expanded at around 5% CAGR

The U.S is expected to account for 40% of overall sales of plasma fractionation during the projected forecast period

Demand for plasma fractionation in Asia is likely to expand at a CAGR of 8% through 2031

Plasma fractionation for treating neurological disorders is anticipated to rise, expanding at a CAGR of 7.2%

Technological advancements in fractionation techniques along with and regular check-ups to detect possible neurological conditions will impact the growth of plasma fractionation

Companies such as CSL Behring, Shire plc, Sanquin, Biotest AG, GRIFOLS, Baxter International Inc., Kedrion, Octapharma USA Inc are leading the plasma fractionation.

The neurology segment is expected to account for more than two-fifths of the plasma fractionation market.

The immunology segment is likely to be valued at US$ 10 Bn in the forecast period.

Need an Exclusive Report for your Unique Requirement?

- Our Clients -

Report Client

- Evaluate How Fact.MR's Report Can Help. -

Is the market research conducted by Fact.MR?

Yes, the report has been compiled by expert analysts of Fact.MR, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.

What research methodology is followed by Fact.MR?

Fact.MR follows a methodology that encompasses the demand-side assessment of the market, and triangulates the same through a supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions.

What are the sources of secondary research?

Fact.MR conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.

Who are the respondents for primary research?

Fact.MR speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.

Is a sample of this report available for evaluation?

Yes, you can request a sample, and it will be sent to you through an email.